Editorial Board

Victoria Samanidou PhD (Aristotle University of Thessaloniki, Thessaloniki, Greece). orcid.org/0000-0002-8493-1106
Dr. Victoria Samanidou is Full Professor and Director of the Laboratory of Analytical Chemistry in the Department of Chemistry of Aristotle University of Thessaloniki, Greece and since 2016 the elected President of the Steering Committee of the Association of Greek Chemists-Regional Division of Central & Western Macedonia.
Her research interests focus on the development of sample preparation methods using sorptive extraction prior to chromatographic analysis. She has co-authored 198 original research articles in peer-reviewed journals and 58 reviews, 64 editorials, and 51 chapters in scientific books (h-index 40, Source Scopus, February 2022). She is editorial board member of more than 30 scientific journals and guest editor in more than 27 special issues. She has peer-reviewed more than 683 manuscripts for 148 scientific journals.
In 2021 she was included in the “The Analytical Scientist” 2021 Power List of top 100 influential people in analytical science.

Linzhi Chen, PhD (Boehringer Ingelheim Pharmaceuticals, CT, USA).
Dr. Chen Dr. is a Sr. Research Fellow at Boehringer Ingelheim Pharmaceuticals. He received his Ph.D. in organic chemistry from the University of Mons, Belgium where he studied gas-phase ion chemistry by mass spectrometry. After completing his postdoctoral research on ion-molecule reactions, he began his industry career with 3M Co. where he spend 5 years on metabolite identification/profiling, bioanalysis, and pharmacokinetics. He joined Boehringer Ingelheim Pharmaceuticals in 2001 to lead a bioanalytical group in support of small molecule drug development. In recent years he has been providing LC/MS-based bioanalytical support to biotherapeutic development programs and developed a number of LC/MS assays for various biotherapeutic proteins such as nanobodies, Fabs, bispecific, and mAbs, as well as oligonucleotides. His group also developed immunocapture-LC/MS methodology for simultaneous ADA isotyping and semi-quantitation. His recent interest focuses on LC/MS determination of in vivo biomodifications of biotherapeutics and their impact on PK/PD.

Yu-Luan Chen, BSc MSc Ph.D (Sunovion Pharmaceuticals, Marlborough, MA, USA).
Dr. Yu-Luan Chen is currently Senior Director, Bioanalytical Sciences, Clinical Pharmacology, Translational Medicines & Early Development. He received his B.Sc degree (Xiamen), M.Sc. degree (Nanjing), and Ph.D. degree from the University of British Columbia (Canada). His expertise includes Bioanalytical Sciences and Analytical Chemistry with a special focus in Separation Sciences and LC-MS/MS technologies applying to clinical pharmacokinetics /pharmacodynamics (PK/PD), drug metabolism research, and biomarker assays. Dr. Chen is the editor, Feature Articles for Chinese-American Chemical Society (CACS) Communications, an editorial board member for Journal of Molecular and Applied Bioanalysis, Drug Metabolism Letters, and The Open Spectroscopy Journal. Dr. Chen has published over 50 peer-reviewed papers and three book chapters. His current research interests include bioanalytical LC-MS/MS method development, bioanalytical method validation, PK/PD sample analysis, in vitro and in vivo drug metabolism (cold and hot approaches), biomarker assays, microsampling technologies, and supporting drug discovery and development from nonclinical exploratory through GLP toxicology, and from clinical Phase I through new drug application further to post-approval commitments.

Irene Panderi BSc PhD, (University of Athens, Athens, Greece).
orcid.org/0000-0003-3190-0127
Irene Panderi is a Professor of Pharmaceutical Analysis at the Laboratory of Pharmaceutical Analysis, Faculty of Pharmacy, National and Kapodistrian University of Athens. Irene Panderi is a pharmacist with over 20 years experience in leading research in the fields of Pharmaceutical Analysis and Analytical Chemistry developing analytical methods for the analysis of drugs, metabolites, and bioactive compounds in pharmaceuticals, cosmeceuticals, biological fluids, and human tissues. These methods are applied to clinical testing, toxicology studies, doping control, and quality control of drugs. She is also a member of the Scientific Committee on Consumers Safety (SCCS).

Rob J. Vreeken PhD, (Discovery Sciences, Janssen Pharmaceutica, Beerse, Belgium). orcid.org/0000-0003-3568-1371
received his Ph.D. from the Free University of Amsterdam (NL). Hereafter, he developed and applied a variety of MS-based techniques for quantitative and qualitative analysis in academic and commercial settings (PD at EPFL (Lausanne, CH) and group leader at KWR (Netherlands Drinking Water Research facility) and TNO (CRO and research institute)). Subsequently, he headed the Waters EU applications, training, demonstration, and support organizations. After leading the pharma-unit at Avantium (CRO, Amsterdam, NL) he joined the Netherlands Metabolomics Centre (Leiden Academic Centre for Drug Research, Leiden University, NL) as Assistant Professor to create and direct the Central Lab facility. Next to teaching, he developed novel strategies for e.g. (endogenous) metabolite identification and advanced lipidomics, which were used for biomarker discovery in inflammatory processes. From July 2014 he directs a team at Janssen Pharmaceutica (Johnson & Johnson, Beerse, Belgium) focusing on early-stage pathway engagement studies, bioanalysis, and biomarker validation.

Sophie Ayciriex MSc PhD, (ANABIO-MS Laboratory, Institute of Analytical Sciences, Villeurbanne, France).
earned her M.Sc. degree in Biochemistry and Structural Biology at the University Paul Sabatier (Toulouse, France). She obtained her European Ph.D. degree in Biochemistry in 2010 at the University of Bordeaux Segalen, France. During her Ph.D. fellowship, she investigated the characterization of a novel lysolipid acyltransferase in S. cerevisiae by combining several biochemistry tools and lipidomics. For her first post-doctoral fellowship, she joined the University Paris Descartes – Faculty of Pharmacy (CNRS UMR 8638) in Paris, France. She developed analytic methods for the analysis of sterols and oxysterols by UPLC-ESI-HRMS and conducted lipidomics research in relation to neurodegeneration. She is currently pursuing her postdoc in analytical chemistry, performing shotgun Lipidomics on high-resolution mass spectrometry at Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. System biology of lipid metabolism is one of her main research.

Michel L. Campos, MSc Ph.D (Federal University of Mato Grosso – UFMT, Sinop, Brazil).
Dr. Campos received his MSc and PhD in Pharmaceutical Sciences from Sao Paulo State University “Julio de Mesquita Filho” – Faculty of Pharmaceutical Sciences, Brazil (2015), with part of the research in the Centre for Research in Mass Spectrometry at York University, Canada. He worked as a postdoctoral fellow and substitute professor at the Federal University of Paraná, Brazil. He joined the Health Sciences Institute at the Federal University of Mato Grosso as an Adjunct Professor in 2018. His major research interests are Clinical Pharmacokinetics, Pharmacokinetics and Pharmacodynamics, Preclinical Testing of New Drugs and Medicines, Metabolites Investigation by High-Resolution Mass Spectrometry, and Development and Validation of Bioanalytical Methods by HPLC and LCMS. Academic experience in Clinical Pharmacology, Clinical Pharmacokinetics applied to Dose Determination, Therapeutic Drug Monitoring, and Dose Adjustment of Antibiotics from Pharmacokinetic and Pharmacodynamic parameters.

Constantinos Pistos PhD (West Chester University, West Chester, PA, USA).
Dr. Pistos graduated from the department of pharmacy of the Aristotle University of Thessaloniki (Greece) in 1995, before he pursued his M.Sc. and Ph.D studies, at the Department of Pharmacy of the University of Athens (Greece). In 2001-2002 he continued his research as a postdoctoral fellow at the college of pharmacy of the University of Georgia Athens, GA (U.S.A.), before serving as director of a private CRO pharmaceutical company in Greece. Between 2006 and 2012, he possessed the position of Lecturer and by 2012 of Assistant Professor in Toxicology at the School of Medicine of the University of Athens (Greece). By 2015, Dr. Pistos possesses the position of Assistant Professor of Toxicology at the Department of Chemistry at West Chester University of Pennsylvania, U.S.A. He has published fifty-two articles and four book chapters while he presented thirty-five research works in congresses, in the fields of toxicology and pharmaceutical analysis.

Chukwunonso Nwabufo MSc (Gilead Sciences Alberta ULC, Edmonton AB, Canada).
Chukwunonso is an accomplished Pharmaceutical Scientist with over 4 years of experience in drug development across academia and the pharmaceutical industry. He provides an extensive range of analytical chemistry services to support drug development programs and was recently involved in the development of Remdesivir. He has received over 10 awards for research, academic, and leadership accomplishments. His current research interest is on the enhancement of the clinical efficacy and effectiveness of respiratory and neurological medicines. Pharmacokinetics, Pharmacodynamics, and Drug Metabolism Community. Prior to joining Gilead Sciences, he completed an MSc in Pharmacy with distinction at the University of Saskatchewan with a research focus on the preclinical development of novel therapeutic agents for Parkinson’s disease. Chukwunonso completed an undergraduate program in Biochemistry at the University of Benin with First class honors and thesis research that was primarily focused on the effect of Hibiscus Sabdariffa extract on the reproductive hormones of male Wistar rats.

Tao Niu PhD (Vertex Pharmaceuticals, Boston, MA, 02210, USA).
Dr. Niu, is currently an associate director in the clinical & quantitative pharmacology department at Vertex Pharmaceuticals. Dr. Niu has specialized in population PK, PKPD, exposure-response, pediatric label extension using exposure matching, longitudinal model-based meta-analysis, Bayesian modeling, and clinical trial simulation with a focus on rare diseases. Dr. Niu is the pharmacometrics lead and has 10 years of hands-on experience in biologics PK assay, especially in assessing the impact of anti-drug antibodies on PK assays. Dr. Niu is also an expert in immunogenicity, particularly for protein therapeutics and in vivo gene therapy. He is representing Vertex (previously Pfizer) in the IQ Consortium Immunogenicity Working Group. Tao received his PhD in pharmaceutics from the University of Houston. Dr. Niu also holds an MS in pharmacometrics from the University of Maryland and is working towards a second MS in data science from the Georgia Institute of Technology. Dr. Niu’s main research interest is to facilitate drug development with innovative bioanalytical assays and quantitative models with a special focus on in vivo gene therapy.

Abhisheak Sharma, B Pharm M Pharm Ph.D. (Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA).
Dr. Sharma earned his Ph.D. in pharmacokinetics and metabolism from CSIR-Central Drug Research Institute, Lucknow, India. He is a trained analytical scientist, pharmacokinetisist, and pharmacist whose research focuses on the in vivo and in vitro preclinical pharmacokinetic studies of new chemical entities and natural products. He is proficient in various approaches to bioanalytical method development and validation of discovery compounds and plant alkaloids in different biological matrices (blood, dried blood spot, plasma, serum, tissue homogenates, and urine) using various analytical techniques (UPLC-MS/MS, UPLC-PDA-MS, and UPLC-PDA/FL). His research interests include translational development of new chemical entities to candidate drugs using PK-PD modeling and simulation approach.

Abraham Samuel Finny, Ph.D. (Waters Corporation, Milford, MA, USA).
Dr. Finny is a Senior Scientist at Waters Corporation, Milford, MA, USA. He received his M.S. in Biomedical Engineering from the University of Strathclyde, Glasgow, Scotland, UK, where he studied controlled drug delivery systems. He earned his Ph.D. in Chemistry at Clarkson University, Potsdam, NY, USA, where he worked on developing additive manufacturing platforms and 3D printable formulations for sensing and environmental applications. Apart from his solid academic teaching and research experience, Abraham has high-quality industrial R&D experience spanning over three years as an analytical scientist working for leading multinational biopharmaceutical and biotechnology companies. Some of his research interests include analytical chemistry, biomaterials, bioprocessing, additive biomanufacturing, and automation techniques in the field. Abraham has authored multiple research articles, book chapters, and review articles.

Unnati Kapadnis, B.Pharm, M.Pharm, M.S. (Agios Pharmaceuticals, Cambridge, MA, USA).
Mrs. Kapadnis is an experienced bioanalytical scientist currently working in DMPK department at Agios Pharmaceuticals. She has over 7 years of experience in the method development and validation of drug candidates and biomarkers using analytical technologies including HPLC, LC-MS/MS, and ligand binding assays(ELISA). She has an excellent understanding of Good Laboratory Practices (GLP) and Clinical Laboratory Improvement Amendments (CLIA) for method validation and sample analysis. She works in cross-functional teams to collaborate with drug early-stage discovery, preclinical safety, translational sciences, and clinical development scientist to devise and implement analytical solutions. Mrs. Kapadnis oversees the generation of quality data to study the Pharmacokinetics (PK), Pharmacodynamics (PD), and Toxicokinetics (TK) of novel drug candidates. Her current research interests include developing novel analytical assays, fine-tuning microsampling techniques, optimizing sample collection, extraction, and purification processes to achieve optimal separation using chromatography, developing and optimizing analytical processes, and evaluating emerging analytical technologies for acquisition purposes.